BDTX
Black Diamond Therapeutics Inc

2,672
Mkt Cap
$124.78M
Volume
639,557.00
52W High
$4.94
52W Low
$1.20
PE Ratio
6.04
BDTX Fundamentals
Price
$2.23
Prev Close
$2.19
Open
$2.11
50D MA
$2.43
Beta
1.95
Avg. Volume
651,807.66
EPS (Annual)
-$1.27
P/B
0.99
Rev/Employee
$0.00
$41.37
Loading...
Loading...
News
all
press releases
Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock
Wedbush upped their price objective on shares of Black Diamond Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research note on Tuesday...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
Black Diamond Therapeutics (NASDAQ:BDTX) Releases Earnings Results
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the...
MarketBeat·1d ago
News Placeholder
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.
Zacks·9d ago
News Placeholder
Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference
Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight progress for its lead program, silevertinib, a fourth-generation epidermal...
MarketBeat·12d ago
News Placeholder
Black Diamond Therapeutics (BDTX) Expected to Announce Quarterly Earnings on Thursday
Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat·20d ago
News Placeholder
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of "Moderate Buy" by Analysts
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat reports. One...
MarketBeat·25d ago
News Placeholder
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 0.5% - Here's Why
Black Diamond Therapeutics (NASDAQ:BDTX) Trading 0.5% Higher - Here's Why...
MarketBeat·28d ago
News Placeholder
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) DelveInsight
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...
PR Newswire·1mo ago
News Placeholder
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the...
MarketBeat·2mo ago
News Placeholder
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Zacks·2mo ago
<
1
2
...
>

Latest BDTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.